Critical Appraisal of Published Indirect Comparisons and Network Meta-Analyses of Competing Interventions for Multiple Myeloma

The objective of the current study was to evaluate the relevance and credibility of published NMA and unanchored MAIC studies aiming to estimate the comparative efficacy of treatment options for RRMM.
Source: Value in Health - Category: International Medicine & Public Health Authors: Source Type: research

Related Links:

Conditions:   Recurrent Aggressive Non-Hodgkin Lymphoma;   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent High Grade B-Cell Lymphoma;   Recurrent Malignant Neoplasm;   Recurrent Plasma Cell Myeloma;   Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma;   Refractory  Aggressive Non-Hodgkin Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma;   Refractory High Grade B-Cell Lymphoma;   Refractory Malignant Neopla...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Blood Cancer Journal, Published online: 01 June 2020; doi:10.1038/s41408-020-0331-4Blockade of VLA4 sensitizes leukemic and myeloma tumor cells to CD3 redirection in the bone marrow microenvironment
Source: Blood Cancer Journal - Category: Hematology Authors: Source Type: research
A 51-year old man in his fourth-line with daratumumab after two autologous cell transplantation for an IgG-kappa myeloma was admitted to the intensive care unit for septic shock with multi-organ failure. On examination, he had febrile respiratory failure with left inferior lobe pulmonary crackling. The skin was covered with diffuse painful nodular ringworm-shaped lesions surrounded by an erythematous halo without mucosal involvement Fig. 1, Panel A and B. Biology showed arterial hyperlactatemia at 9.5  mmol/l and pancytopenia.
Source: International Journal of Infectious Diseases - Category: Infectious Diseases Authors: Tags: Medical Imagery Source Type: research
Publication date: Available online 30 April 2020Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Alessandra Malato, Elena Rossi, Mario Tiribelli, Francesco Mendicino, Novella Pugliese
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Knockdown of ubiquitin‑specific protease 51 attenuates cisplatin resistance in lung cancer through ubiquitination of zinc‑finger E‑box binding homeobox 1. Mol Med Rep. 2020 May 27;: Authors: Zhou F, Du C, Xu D, Lu J, Zhou L, Wu C, Wu B, Huang J Abstract Lung cancer is a devastating cancer with high morbidity and mortality. Ubiquitin‑specific protease (USP) is a type of deubiquitinating enzyme (DUB) that has been implicated in numerous cancers, including colorectal, myeloma and breast. In the present study, the expression of USP51 was determined in the lung cancer cell line A549 and cisplatin (a...
Source: Molecular Medicine Reports - Category: Molecular Biology Tags: Mol Med Rep Source Type: research
Authors: Pablo A, Breaud AR, Clarke W Abstract Bone marrow transplantation is used to treat particular types of cancers such as lymphoma, leukemia, and multiple myeloma. Appropriate dosing of busulfan during the preparative phase is critical for a successful allograft; if blood concentrations get too high significant liver toxicity can occur, if blood concentrations are too low, then graft-versus-host disease (GVHD) can develop. Busulfan monitoring in blood allows hospitals with the opportunity to provide individualized medicine to patients and improve overall patient outcome. Liquid Chromatography-Tandem Mass Spec...
Source: Current Protocols in Toxicology - Category: Toxicology Tags: Curr Protoc Toxicol Source Type: research
Teclistamab appeared to be a safe and efficacious treatment for patients with relapsed/refractory multiple myeloma, according to a phase I study presented at the ASCO Virtual Scientific Program.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Source Type: news
Publication date: Available online 29 May 2020Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Alexander Coltoff, Ruben Mesa, Jason Gotlib, Jessica Shulman, Raajit K. Rampal, Olivia Siwoski, Abdulraheem Yacoub, Alison Moliterno, Anna Yang, Evan Braunstein, Aaron T. Gerds, Gabriela S. Hobbs, Elliott F. Winton, Swati Goel, Martha Wadleigh, Douglas Tremblay, Erin Moshier, John Mascarenhas
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: Available online 29 May 2020Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Stefania Crisci, Elvira Pota, Giancarla Iaccarino, Irene Postiglione, Concetta Meo, Sara Mele, Rosaria De Filippi, Antonio Pinto
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: Available online 29 May 2020Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Nitya Nathwani, Joycelynne Palmer, Timothy W. Synold, Behrouz Salehian, Michael Rosenzweig, James F. Sanchez, Samantha N. Hammond, Kehinde Adekola, Valeria Tomarchio, Arnab Chowdhury, Chatchada Karanes, Myo Htut, Firoozeh Sahebi, Tanya Siddiqi, Amrita Krishnan, Stephen J. Forman, Steven T. Rosen
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
More News: International Medicine & Public Health | Myeloma | Study